RIGL is the ticker symbol for RIGEL PHARMACEUTICALS INC, a publicly traded Healthcare sector company listed on Nasdaq. 13F Pro tracks RIGL with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is RIGL a good stock to buy?

13F Pro's AI ranking engine scores RIGL at 73.8/100, ranked #123 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for RIGL is available at https://13fpro.ai/company/RIGL. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source RIGL data?

All RIGEL PHARMACEUTICALS INC fundamentals and ownership data come directly from SEC EDGAR. RIGEL PHARMACEUTICALS INC files with the SEC under CIK 1034842. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

RIGEL PHARMACEUTICALS INC RIGL

NasdaqSmall CapHealthcare

13F Pro quality score

Rank #123 of 2,925TOP 5%

Why it scores 74 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$78.70M

Quarter to Jun 30

Net income

$17.29M

Quarter to Jun 30

Operating margin

29.9%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$640.43M total

BlackRock, Inc.

$75.89M+9.7%

Soleus Capital Management, L.P.

$72.12MNew

ARMISTICE CAPITAL, LLC

$65.41M+30.6%

STATE STREET CORP

$40.68M-7.2%

VANGUARD CAPITAL MANAGEMENT LLC

$30.71M+2.7%

AMERICAN CENTURY COMPANIES INC

$29.02M+36.2%

LSV ASSET MANAGEMENT

$28.23M+20.0%

ACADIAN ASSET MANAGEMENT LLC

$23.14M-11.2%

D. E. Shaw & Co., Inc.

$21.22M+21.7%

GEODE CAPITAL MANAGEMENT, LLC

$18.91M+9.7%

MARSHALL WACE, LLP

$14.37M-38.6%

CM Management, LLC

$9.78M+6.4%

VANGUARD PORTFOLIO MANAGEMENT LLC

$9.14M+58.4%

DIMENSIONAL FUND ADVISORS LP

$8.92M-39.9%

GOLDMAN SACHS GROUP INC

$8.87M-48.4%

TWO SIGMA INVESTMENTS, LP

$8.12M-48.8%

NOMURA ASSET MANAGEMENT INTERNATIONAL INC.

$7.63MNew

MORGAN STANLEY

$7.28M+88.2%

CHARLES SCHWAB INVESTMENT MANAGEMENT INC

$6.05M-12.6%

NORTHERN TRUST CORP

$5.73M+8.8%

RENAISSANCE TECHNOLOGIES LLC

$5.71M-56.9%

O'SHAUGHNESSY ASSET MANAGEMENT, LLC

$5.13M+4.4%

AQR CAPITAL MANAGEMENT LLC

$4.88M+37.1%

BRIDGEWAY CAPITAL MANAGEMENT, LLC

$4.86MNew

Nuveen, LLC

$4.85M-63.3%

See all 156 institutional holders →

What's Driving RIGL's Business? Latest 10-Q Breakdown

33/33 datapoints verified

AI-extracted from the 10-Q filed 2026-08-04 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Total revenue fell 23% to $78.7M as a prior-year $40.0M Lilly cost-share release did not repeat, while net product sales rose 14% to $67.0M.

Biggest Revenue Drivers

Product sales, net$67.0M+$8.1M YoY

Improved trends across the portfolio as first-quarter seasonal access-related factors moderated

Contract revenues from collaborations and other$11.7M-$31.0M YoY

Prior-year quarter included $40.0M non-cash release of Lilly cost share liability; current quarter included $4.0M milestone revenue

Biggest Revenue Drivers

Total revenue: $78.7M-23% YoY

Product sales, net$67.0M+$8.1M YoY

Improved trends across the portfolio as first-quarter seasonal access-related factors moderated

Within Product sales, net

TAVALISSE$47.4M+18% YoY

Primarily driven by higher volumes and higher price per bottle, plus lower revenue reserves

GAVRETO$10.7M-10% YoY

Lower volumes and higher revenue reserves, partially offset by higher price per bottle

REZLIDHIA$8.9M+27% YoY

Higher volumes and higher price per bottle, partially offset by higher revenue reserves

Contract revenues from collaborations and other$11.7M-$31.0M YoY

Prior-year quarter included $40.0M non-cash release of Lilly cost share liability; current quarter included $4.0M milestone revenue

Largest Expense Items

Selling, general and administrative$32.6M+$3.4M YoY

Increased personnel-related costs of $2.6M from higher stock-based compensation and other employee costs

Research and development$14.0M+$7.1M YoY

Clinical trial expenses up $2.7M, personnel costs up $2.4M, and $1.5M reimbursable Arvinas/Pfizer development costs

Cost of product sales$8.5M+$4.0M YoY

Product costs up $2.6M on timing of partner drug supply deliveries and higher sales, plus $1.1M higher royalties

Provision for income taxes$6.3M+$5.9M YoY

Federal tax expense of $5.3M recognized after release of the full valuation allowance in Q4 2025

Margins: Cost of product sales nearly doubled to $8.5M as post-approval inventory reflects full manufacturing cost, higher royalties, and partner supply deliveries. Income from operations fell to $23.6M from $61.1M.

Watch Items from the Filing

McKesson accounted for 46% and Cencora 21% of total net product sales and collaboration revenues in the quarter, up from 31% and 12%.
Lilly terminated the collaboration effective June 15, 2026; no future milestones or royalties expected, and Lilly went from 39% of revenue to zero.
Paid $70.0M upfront for VEPPANU license with up to $15.0M more in fees, $60.0M regulatory and $260.0M commercial milestones, plus $40.0M development funding cap.
Cash, equivalents and short-term investments fell to $95.3M from $155.0M; $40.0M drawn on the revolving facility at quarter end, $32.0M repaid in July.
Take-or-pay VEPPANU supply commitment of about $26.8M through 2030, plus $16.3M TAVALISSE manufacturing obligation subject to cancellation fees.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/RIGL

Earnings Per Share

13fpro.ai/company/RIGL

Loading ratio trend…

RIGEL PHARMACEUTICALS INC reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$294.3M	$367.0M	42.6%
FY 2024	10-K	$179.3M	$17.5M	13.5%
FY 2023	10-K	$116.9M	$-25.1M	-17.5%
FY 2022	10-K	$120.2M	$-58.6M	-46.2%
FY 2021	10-K	$149.2M	$-17.9M	-8.4%
FY 2020	10-K	$108.6M	$-29.7M	-26.7%

About RIGEL PHARMACEUTICALS INC (RIGL): stock profile, AI score and financials

RIGEL PHARMACEUTICALS INC (RIGL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RIGL at 73.8/100 on a composite quality score built from its SEC filings, placing it at rank #123 of 2,925 stocks — the top 5% of the AI-ranked universe. RIGL scores in the top quartile across balance sheet strength (99.9), profitability (99.4), revenue growth (93.2). Areas of concern include revenue scale (28.4), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), RIGEL PHARMACEUTICALS INC reports quarterly revenue of $78.7M, net income of $17.3M, an operating margin of 29.9%. Top institutional holders of RIGL by reported 13-F value include BlackRock, Soleus Capital Management, L.P., ARMISTICE CAPITAL, based on the most recent SEC filings. RIGL trades on the Nasdaq exchange and files with the SEC under CIK 1034842. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RIGL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for RIGEL PHARMACEUTICALS INC directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1034842 →

RIGEL PHARMACEUTICALS INC RIGL

Top Institutional Holders

What's Driving RIGL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

RIGL key financials by period

RIGL insiders

About RIGEL PHARMACEUTICALS INC (RIGL): stock profile, AI score and financials

RIGEL PHARMACEUTICALS INC RIGL

Top Institutional Holders

What's Driving RIGL's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

RIGL key financials by period

Companies similar to RIGL

RIGL insiders

About RIGEL PHARMACEUTICALS INC (RIGL): stock profile, AI score and financials